FORMOTEROL (Easyhaler®)

Clinical Indication

Asthma & COPD

Comments

1st Choice Dry Powder

COPD: The LLR COPD guidelines have been updated (June 2026) and LABAs are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines.

Asthma: formoterol should only be prescribed as part of a combination device (ICS/LABA), and a formoterol single agent inhaler should only be used in the few patients who require ciclesonide MDI as an ICS (licence > 6 years).

In use shelf-life: 4 months

Date of classification

May 2026